Pierre Mordant

Prof. Pierre Mordant


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
RRRégis Renard
Régis Renard
AGAntoine Girault
Antoine Girault
AAAlla Avramenko-Bouvier
Alla Avramenko-Bouvier
ARArnaud Roussel
Arnaud Roussel
PCPierre Cerceau
Pierre Cerceau
ZBZohra Brouk
Zohra Brouk

1 May 2021 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
JLJean-Baptiste Leclère
Jean-Baptiste Leclère
LFLudovic Fournel
Ludovic Fournel
HEHarry Etienne
Harry Etienne
CZCharbel Al Zreibi
Charbel Al Zreibi
IOilaria onorati
ilaria onorati
PMPierre Mordant
Pierre Mordant

29 August 2022 in Clinical Lung Cancer
Verified
Journal Article
Open access
PMPierre Mordant
Pierre Mordant
SBSolenn Brosseau
Solenn Brosseau
BMBernard Milleron
Bernard Milleron
NSNicola Santelmo
Nicola Santelmo
SFSéverine Fraboulet-Moreau
Séverine Fraboulet-Moreau
VWVirginie Westeel
Virginie Westeel
Molecular profile of resected stage I-II non-small cell lung cancer (NSCLC) would help refine prognosis and personalize induction or adjuvant strategies. We sought to report the molecular profile of resected stage I-II NSCLC and analyzed the impact of epidermal growth factor receptor (EGFR) mutations on outcomes in a Western population. Surgical cases were identified from Biomarkers France study, a nationwide prospective study including NSCLC patients screened for EGFR, HER2, KRAS, BRAF, PIK3CA, ALK alterations from 2012 to 2013. Among surgical patients, clinical charts of the largest centers were reviewed in order to analyze the prognostic impact of EGFR mutations. In the BMF database (n = 17.636), surgical patients (n = 854) were characterized by a higher proportion of EGFR mutations than nonsurgical patients (12.9% vs. 10.2%, P = .025), while the other molecular alterations did not differ. The proportion of EGFR mutations was 27% in women undergoing surgery. In the study group (n = 293; EGFR wild type, n = 235; usual mutation, n = 50; rare mutation, n = 8), after a median follow-up of 67 months, 215 patients (74.4%) had not relapsed. No difference was found between EGFR-mutant and EGFR-wt tumors regarding recurrence site, disease-free survival, and overall survival. The 5-year disease-free survival and overall survival after surgical resection of stage I-II EGFR-mutated tumors were 65% and 75%, respectively. In resected stage I to II NSCLC, EGFR mutations were found in 12.9% of cases, associated with a 5-year overall survival of 75%, with no impact on recurrence site, disease-free survival, and overall survival.

19 September 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TBTifanie Brockaert
Tifanie Brockaert
IFInês Ferreira
Inês Ferreira
ALAnne Laplante
Anne Laplante
PFPaul Fogel
Paul Fogel
DGDavid Grimbert
David Grimbert
PMPierre Mordant
Pierre Mordant
Background: Peripheral femoro-femoral veno-arterial extracorporeal membrane oxygenation is increasingly used in refractory cardiogenic shock. However, the obstruction of the femoral artery by the return cannula could lead to acute limb ischemia, a frequently encountered situation that is inconstantly prevented by the adjunction of a distal perfusion cannula (DPC). The aim of this study was to investigate the influence of three physical parameters on the perfusion of the cannulated lower limb. Methods: Using patient-specific arterial models and computational fluid dynamic simulations, we studied four diameters of arterial cannula, three diameters of DPC, and two percentages of arterial section limitation. Results: We found that adequate perfusion of the cannulated limb was achieved in only two out of the twenty-one configurations tested, specifically, when the arterial cannula had a diameter of 17 Fr, was considered to limit the section of the artery by 90%, and was associated with an 8 Fr or a 10 Fr DPC. Multivariable analysis revealed that the perfusion of the cannulated lower limb was correlated with the diameter of the DPC, but also with the diameter of the arterial cannula and the percentage of arterial section limitation. Conclusions: In most of the cases simulated here, the current system combining unsized arterial cannula and non-specific DPC was not sufficient to provide adequate perfusion of the cannulated lower limb, urging the need for innovative strategies to efficiently prevent acute limb ischemia during peripheral femoro-femoral veno-arterial extracorporeal membrane oxygenation.

16 March 2024 in Journal of Robotic Surgery
Verified
Journal Article
Closed access
PDF file
LBLéa Betser
Léa Betser
ABAlicia Le Bras
Alicia Le Bras
HEHarry Etienne
Harry Etienne
ARArnaud Roussel
Arnaud Roussel
ABAntonio Bobbio
Antonio Bobbio
PMPierre Mordant
Pierre Mordant

1 August 2018 in Transplantation
Verified
Journal Article
Closed access
AHAngela Hin
Angela Hin
CKCaroline Kannengiesser
Caroline Kannengiesser
ARArnaud Roussel
Arnaud Roussel
BRBenjamin Renaud-Picard
Benjamin Renaud-Picard
ARAntoine Roux
Antoine Roux
PMPierre Mordant
Pierre Mordant
BackgroundClub Cell Secretory Protein (CCSP) G38A polymorphism has recently been involved in lung epithelial susceptibility to external injuries. Lung transplantation (LT) is currently limited by ischemia-reperfusion injury leading to primary graft dysfunction (PGD). We thus hypothesized that donor CCSP G38A polymorphism might impact the risk of PGD after LT. Methods We focused on LT included in the French multicentric Cohort in Lung Transplantation (COLT), performed between January 2009 and December 2014, and associated with preoperative blood samples from the donor and the recipient. Characteristics of the donors, recipients, procedures, early and late outcomes were prospectively recorded in COLT. The CCSP serum concentration and CCSP gene G38A polymorphism were retrospectively determined in a blind manner. Their association with grade 3 PGD was studied in univariate and multivariate analysis. Results The study group included 104 LT donors and recipients, 84 with grade 0 to 2 PGD and 20 with grade 3 PGD. Preoperative CCSP serum concentration was significantly higher in the donors (median, 22.54 ng/mL; interquartile range, 9.6-43.9) than in the recipients (median, 7.03 ng/mL; interquartile range, 0.89-19.2; P < 0.001) but none impacted the risk of grade 3 PGD (P = 0.93 and P = 0.69, respectively). Donor CCSP G38A polymorphism was associated with a decreased risk of grade 3 PGD in univariate (AG + AA 3/21 = 14.2% vs GG 10/26 = 38.4%, P = 0.044) and multivariate analysis (odds ratio associated with AG + AA, 0.22; 95% confidence interval, 0.041-0.88; P = 0.045), but recipient CCSP G38A polymorphism was not. Conclusions Donor CCSP G38A polymorphism is associated with a decreased risk of severe PGD after LT in the COLT study. These findings should be confirmed in the frame of a prospective study.